Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
Immutep tries again
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
